Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

Examiner

Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

C mplete if Kn wn				
Application Number	10/721,007			
Filing Date	November 21, 2003			
First Named Inventor	Guido Di Napoli			
Art Unit	1653			
Examiner Name	Snedden			
Attorney Docket Number	16696-10			

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
55		^{US-} 5411952	05-02-1995	Kaswan	
65		^{US-} 5474979	12-12-1995	Ding et al.	
SS		^{US-} 5739105	04-14-1998	Kim et al.	
SS		^{US-} 5929048	07-27-1999	Falk et al.	
55		^{US-} 5951971	09-14-1999	Kawashima et al.	
		US-			
		US-`			
		US-			
		US-	1		*
		US-			
		US-			
		US-			
		US-		,1	
		US-			
		US-			
-	-	US-			
		US-			· .
		US-			
		US-			

			ON PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
·		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T6
SS		WO89/01772	03-09-1989	Kaswan		
SS		WO93/23010	11-25-1993	Sandoz-Pharmace		
53		WO95/31211	11-23-1995	Ding et al.		
•	-					┢

11/05/2004 *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Date Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03) Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Numb r 007 INFORMATION DISCLOSURE Filing Dat November 21, 2003 STATEMENT BY APPLICANT First Named Inventor Guido Di Napoli Art Unit (Use as many sheets as necessary) **Examiner Name Attorney Docket Number** Sheet 2 16696-10

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
55		Condon, Patrick et al., Double-blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy, Br. J. of Ophthalmol 1999; 83:1121-1124.		
5>		Gowland, G., Fourfold Increase in Efficiency of Cyclosporin A when Combined With Hyaluronan: Evidence for Mode of Drug Transport and Targeting, Int. J. Immunotherapy XIV(1) 1-7 (1998).		
55		Gowland, G. et al., Marked Enhanced Efficacy of Cyclosporin When Combined with Hyaluronic Acid, Clin. Drug. Invest 11(4) 245-250 1996.		
		XP-002172972		
×				
	·			
Examiner	Ī	Date (1/7/4)/		
Signature	1	Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.